These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8192468)

  • 1. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Feb; 38(2):369-70. PubMed ID: 8192468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; Trujillano I; García Sánchez E; García García MI; Fresnadillo MJ
    Antimicrob Agents Chemother; 1995 May; 39(5):1194-5. PubMed ID: 7625815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.
    Ford AS; Baltch AL; Smith RP; Ritz W
    J Antimicrob Chemother; 1993 Apr; 31(4):523-32. PubMed ID: 8390434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activities of eight quinolones against members of the Bacteroides fragilis group.
    Borobio MV; Conejo M; Ramirez E; Suarez AI; Perea EJ
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1442-5. PubMed ID: 8092852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.
    Carlyn CJ; Doyle LJ; Knapp CC; Ludwig MD; Washington JA
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1606-8. PubMed ID: 7492114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of new quinolones against ciprofloxacin-resistant staphylococci.
    Forstall GJ; Knapp CC; Washington JA
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae.
    Knapp JS; Neal SW; Parekh MC; Rice RJ
    Antimicrob Agents Chemother; 1995 Apr; 39(4):987-9. PubMed ID: 7786010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
    Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
    Zhanel GG; Karlowsky JA; Hoban DJ
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):343-7. PubMed ID: 9635908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activities of new quinolones against coryneform bacteria.
    Martínez-Martínez L; Suárez AI; Ortega MC; Perea EJ
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1439-41. PubMed ID: 8092851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.
    Cohen MA; Yoder SL; Huband MD; Roland GE; Courtney CL
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2123-7. PubMed ID: 8540728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of CP-74667 compared with four other fluoroquinolones.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):531-6. PubMed ID: 1330419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of CS-940, a new trifluorinated quinolone.
    Biedenbach DJ; Sutton LD; Jones RN
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2325-30. PubMed ID: 8619590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
    Knapp JS; Hale JA; Neal SW; Wintersheid K; Rice RJ; Whittington WL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG; Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
    Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.